...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study.
【24h】

Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study.

机译：帕米膦酸对乳腺癌伴骨转移的疗效：一项随机，双盲，安慰剂对照的多中心研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE: To evaluate the efficacy of pamidronate 60 mg i.v. q 4 weeks in women with advanced breast cancer with skeletal metastases. PATIENTS AND METHODS: 404 woman with skeletal metastases from breast cancer in Sweden and Norway were included in a randomized, placebo-controlled, multicenter study. Except for the study medication, other palliative treatment was chosen at the discretion of the physician. Skeletal related events, i.e. increased pain, treatment of hypercalcemia, pathologic fractures of long bones or pelvis, paralyses due to vertebral compression, palliative radiotherapy for skeletal metastases, surgery on bone and change of antitumor therapy were recorded every third month as well as a self-estimated pain-score using visual Analog Scales and analgesic consumption. RESULTS: There was a significantly increased time to progression of pain (p < 0.01), to hypercalcemic events (p < 0.05) as well as for the cumulative number of skeletal related events (p < 0.01) in favor for the pamidronate group. No statistically significant reduction of pathologic fractures of long bones or pelvis, or pareses due to vertebral compression occurred. No statistically significant differences were found for the need of radiotherapy and surgery on bone. The pamidronate group faired better regarding performance status (p < 0.05). There was a statistically not significant lower consumption of opioid analgesics in the pamidronate group (p = 0.14). CONCLUSION: Pamidronate 60 mg i.v. q 4 weeks reduces skeletal events and improves the quality of life in women with bone metastases from breast cancer.
机译：目的：评估帕米膦酸60毫克静脉内注射的疗效。 q对于患有晚期乳腺癌并有骨骼转移的女性，为期4周。患者和方法：瑞典和挪威的404名患有乳腺癌的女性转移性乳腺癌患者被纳入一项随机，安慰剂对照，多中心研究。除研究药物外，其他姑息治疗均由医师决定。每三个月记录一次与骨骼相关的事件，例如疼痛增加，高钙血症的治疗，长骨或骨盆的病理性骨折，椎骨压缩引起的麻痹，骨骼转移的姑息放疗，骨骼手术和抗肿瘤治疗的改变，以及自我视觉模拟量表和止痛药的估计疼痛评分。结果：对于帕米膦酸组，疼痛进展（p <0.01），高钙血症事件（p <0.05）以及骨骼相关事件的累积次数（p <0.01）显着增加。没有发生因椎骨受压而导致的长骨或骨盆或结节的病理性骨折的统计学显着减少。没有发现对骨放疗和手术的需要有统计学上的显着差异。帕米膦酸组的表现状态较好（p <0.05）。在帕米膦酸组中，阿片类镇痛剂的消费量在统计学上没有显着降低（p = 0.14）。结论：帕米膦酸60 mg静脉注射。 q 4周减少骨骼事件并改善患有乳腺癌骨转移的女性的生活质量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号